Urogenital Vaccination: Addressing STIs and Beyond
- Authors: Amana Parveen1, Shekhar Singh2, Dimple Singh Tomar3, Akhil Sharma4, Shaweta Sharma5
-
View Affiliations Hide Affiliations1 PSIT Pranveer Singh Institute of Technology Pharmacy, Jargaon, India 2 Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India 3 Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, India 4 R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India 5 School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India
- Source: Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 1) , pp 173-205
- Publication Date: July 2025
- Language: English
Urogenital Vaccination: Addressing STIs and Beyond, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815324570/chapter-6-1.gif
The emergence of urogenital vaccination as a groundbreaking approach to fight against sexually transmitted infections (STIs) and promote urogenital health is a milestone. In this chapter, preventive healthcare potential with regard to urogenital vaccination is widely explored. It begins by situating the prevalence and consequences of STIs globally in order to stress that better prevention methods are highly required. Novel strategies are needed to address the shortcomings of traditional strategies, such as condoms and behavioral interventions, that present obstacles in the way of wider adoption and effectiveness. This kind of novelty is seen in urogenital vaccination, which offers particular protection against a variety of pathogens that cause STIs, namely chlamydia, gonorrhea, and human papillomavirus (HPV). Also, it can be applied broadly to other urogenital health issues like urinary tract infections (UTIs). This chapter explores the benefits of urogenital vaccination, which include providing long-term protection and simplifying prevention activities, especially in high-risk populations. However, there are still hurdles to be overcome in developing effective vaccines for urogenital pathogens. Ethics surrounding vaccine safety, efficacy, and equitable availability should also be considered for successful implementation. Public health can be transformed by urogenital immunizations, which would lower the transmission rates, reduce the burden linked to STIs, and improve urogenital health outcomes. Nevertheless, long-term research on investment strategies, integration with existing sexual health programs, and sexually transmitted infection (STI) prevention is required in order to achieve these advantages. This chapter demands more cooperation and dedication to realize the full potential of urogenital vaccination as an important preventive mechanism in medicine, as well as healthier lives for individuals and societies all over the world.
-
From This Site
/content/books/9789815324570.chapter-6dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105